Dubai police said on Monday they caught three thieves just hours after they stole a precious pink diamond worth $25 million.
“The Dubai Police General Command has foiled the theft of a very rare pink diamond, valued at $25 million,” the police said in a statement shared by the United Arab Emirates’ official news agency WAM.
A diamond trader who had brought the jewel from Europe was lured to a villa by a crime gang under the pretence of a viewing by a potential wealthy client, police said.
But the gem was stolen when the diamond dealer arrived for the bogus inspection, the statement added.
Within eight hours three people from an unspecified Asian country were arrested “thanks to the efforts of specialised and field teams, and by using the latest artificial intelligence technologies,” police said.
Video footage shared by the Dubai Media Office showed the three men with their faces blurred after their arrest as well as CCTV footage of the gang.
Dubai is an important hub for diamond trading. Tightly controlled and policed, the UAE prides itself on its security and stability.
NordVPN announced today in a that its Meshnet feature will shut down on December 1. All aspects of Meshnet will stop working on that date, though nothing else about NordVPN will be affected. If you were using Meshnet to connect computers, route web traffic through a personal device or share files, you’ll need to find another solution by December.
As I mentioned in my , Meshnet was one of the most envelope-pushing features on any VPN, letting users link their devices through a NordLynx tunnel without needing to go through a third-party server. Once the tunnel was set up, you could access either device through the other one to share files or access services. With enough connected devices, you could check your work email, visit a friend’s media server, play a remote game on another server and watch your home-based TV subscriptions — all from a single laptop anywhere on the planet. Unbelievably, it was even free to use.
I’m sad to see Meshnet go, but as NordVPN’s blog post makes clear, it never found its audience. As exciting as it was to people like me who spend all day squinting at the guts of VPNs, it didn’t provide enough everyday value to catch on with the majority of NordVPN’s customers. Hindsight shows us that Meshnet’s benefits, like remote desktop and file sharing, were mainly business-oriented; selling those was always going to be an uphill battle in a market where .
If you’re one of the few people who was actually using Meshnet, you have a few months to arrange alternatives. Should you want to stay within the NordVPN ecosystem, you can replace its file sharing features with , which gives you 3 GB of storage for free. Of course, Google Drive is also an option. For remote access, NordVPN recommends , a platform where you can connect up to 10 devices without paying.
Keke Palmer just debuted a brand new hairstyle, and it combines two of the hottest trends of fall 2025. While Palmer has been rocking her orange hair for quite some time now, the actor just showed off an ultra cropped pixie cut on her Instagram too. The new look comes just in time for the summer-to-fall transitional season.
On August 17, Palmer posted a series of car selfies, showing off the new haircut. The caption read, “My birthday is just around the corner,” alluding to virgo season, but as it so happens, the new look was the perfect inspo for beyond just that.
Save for the tiniest micro fringe in the front, Palmer’s short haircut was ultra cropped for a super clean look. Committing to the ‘90s trends, Palmer also opted for thin sleek brows, short thick lashes, and ultra glossy lips. A healthy wash of blush gave the style a 2025 update.
With Palmer’s masterclass on how to style the pixie cut, this forecasted trend could take off sooner than expected. Experts say that the pixie cut may be set to make a big comeback in fall 2025. Fitting for back-to-school season, the edgy cut is simplistic and low maintenance for early mornings, but has good payoff. Jerome Lordet, a New York-based hairstylist and owner of Jerome Lordet Salon, told Teen Vogue, “It reveals the face, highlights bone structure, and makes a bold yet refined statement.”
Instagram content
This content can also be viewed on the site it originates from.
Warm ginger hues are also fitting for the fall season naturally. They’ve been a celebrity-favorite lately too. In addition to Keke Palmer, Camila Mendes and Chappell Roan have been rocking these hues as well.
So, if you’re looking to give yourself a little pre-fall makeover, these styles might be something to consider. But if it’s not your cup of tea, no problem. We’ve got 12 other trending hair styles you can check out here.
Clinicians and industry partners continue the race to find the most efficacious therapy for age-related macular degeneration (AMD). A new gene therapy may solve the puzzle for patients with non-neovascular AMD, and more information is coming soon from a Phase 2 trial, according to one retina researcher. Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center in Israel, shared details about VOY-101, a novel, complement-modulating gene therapy for geographic atrophy (GA).
The Eye Care Network caught up with Dr Trivizki at the American Society of Retina Specialists (ASRS) Annual Meeting in Long Beach, California. He explained the mechanisms beyind VOY-101( Perceive Biotherapeutics, Inc.) and the Phase 1 Beyond study (NCT06087458).
“In our talk, we showed that VOY-101 is safe and tolerable,” Dr Trivizki recounted. A 12-month survey of 24 enrolled patients showed there was no dose limiting toxicity, no systemic adverse effects and no ocular adverse effects, he said. “There was a really mild, transient intraocular cell effect that we observed during the study, which passed with topical steroids only, and eventually all patients were off steroids with no recurrence,” Dr Trivizki said. “That led us to the conclusion that we can move ahead to the Phase 2 [trial] which…[dosed the first patient in late June].”
Dr Trivizki went on to explain the mechanism of the treatment, which is designed to provide patients with Complement Factor H gene (CFH) protection. “CFH protection is a protein that was found to protect patients with GA,” Dr Trivizki said. “The idea here is to provide, with one intravitreal injection, the protection effect of CFH…[and] to be able to use the eye as a production for this specific protein, so with a single injection, you can treat the patient for the long term.”
Dr Trivizki explained that the Phase 1 trial had six sites across three countries, with most of the patients in Tel Aviv. The follow-up, Phase 2 trial, Journey, has started enrollment and dosing, and will follow patients to a 12-month primary endpoint, he added.
A new study suggests preload deficiency could be the underlying cause of fatigue and exercise intolerance in people with systemic lupus erythematosus (SLE). Preload deficiency is a condition where the heart’s capacity to fill with blood before pumping (preload) is reduced, leading to symptoms like fatigue and exercise intolerance. Exercise is particularly helpful for people with lupus, and most people with lupus can take part in some form of activity.
A group of 10 women with SLE with debilitating exercise intolerance was studied. The women did not have anemia, active SLE, or other conditions that would cause debilitation. Various cardiac and blood tests were conducted on the women. All study participants showed reduced exercise tolerance, and in five participants, right heart catheterisation during exercise confirmed preload deficiency. To address this, participants were advised to increase fluid intake (to 128 oz/day), increase sodium intake (to more than 5 g/day), and use compression stockings. Ivabradine was added to the regimen when fluids and sodium were not sufficient or tolerated. All participants reported improvement in symptoms. Additionally, the study participants also had low or undetectable NT-proBNP concentrations (a protein released by the heart under stress) which the researchers believe could be a potential biomarker for preload deficiency.
These findings highlight a potentially treatable cause of fatigue and exercise intolerance in some people with SLE. Future research is needed to determine preload deficiency’s prevalence and understand its role in SLE. Learn more about staying active when you have lupus.
Researchers have long known that cancer alters its genome as it evolves. What has been less clear is how, when, and why genomic structures change as cancer progresses. A new Yale study published Aug. 18 in Nature Genetics reveals critical insights and potential biomarkers of stage-specific cancer development.
Using a technique called chromatin tracing, Yale researchers created detailed 3D maps of genome structures in individual cells in mouse models of lung and pancreatic cancers, driven by the cancer-causing gene KRAS. The maps reveal how chromosomes fold and genes are positioned in the cell nucleus. They also chart cancer’s route from pre-cancerous to advanced disease, even identifying different cancer cell states based solely on the 3D structure of their genomes.
“Importantly, using the unprecedented 3D genome maps, we developed new ways to better nominate cancer-driving genes. These are potential new drug targets for lung cancer, the top cause of cancer death worldwide,” says co-senior author Siyuan (Steven) Wang, PhD, associate professor of genetics and cell biology at Yale School of Medicine (YSM).
“On the basic genome biology side, we also discovered a completely new function for how the 3D genome is compartmentalized to enable single cancer cells to progress to more advanced states,” he says.
Co-senior author Mandar Deepak Muzumdar, MD, associate professor of genetics and of internal medicine (oncology) at YSM says: “Although cancers are thought to be quite heterogeneous, what is remarkable is that the global 3D structure of the genome evolves similarly in cancer cells within and across tumors in these models.
“By focusing specifically on these convergent, stereotypical changes, how they are regulated, and how they impact gene expression, we identified novel genes that delineate cancer prognosis and are crucial for cancer cells to grow,” says Muzumdar, who is a member of Yale Cancer Biology Institute and Yale Cancer Center.
The study suggests that the detailed data resulting from this method and its broad application could improve future cancer diagnostics and staging, as well as help identify new therapy targets by understanding what cancerous cells need to survive and thrive.
The study was led by Yale’s Department of Genetics at YSM, including co-first authors Miao Liu, PhD; Shengyan Jin, PhD; and Sherry S. Agabiti, PhD. Other contributors included numerous YSM departments, Yale Cancer Biology Institute, Yale Center for RNA Science and Medicine, Yale Liver Center, and Yale Computational Biology and Biomedical Informatics.
Using the advanced cancer 3D genome mapping methodologies established in this work, the researchers are next investigating additional subtypes of lung and pancreatic cancers and directly studying human patient samples, in collaboration with other investigators at the Yale Cancer Center.
“These 3D genome maps are just the tip of the iceberg,” say Drs. Muzumdar and Wang. “We are just getting started in using this new type of single-cell biologic information to uncover cancer’s untold secrets, aiming to improve treatment and clinical outcomes in the long-term.”
The research reported in this news article was supported by the National Institutes of Health (grants R33CA251037, R01CA292936, R01CA276108-02S1, 5T32GM007205, 2T32GM007499, R01LM013385, DP2CA248136, UH3CA268202, U01CA260701, R01HG011245, DP2GM137414, R01HG012969, 5T32GM00720, and P30CA0163595), AACR-Genentech NextGen Grant for Transformative Cancer Research (19-20-18-MUZU), Yale SPORE in Lung Cancer Career Enhancement Program award (P50CA196530), and Yale University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Breast cancer is one of the most common cancers among women in the United States, second only to skin cancer. Thanks to decades of fundamental research, it’s also one of the most curable. However, challenges remain, especially when confronting aggressive varieties like triple-negative breast cancer.
Cold Spring Harbor Laboratory (CSHL) has a rich history of breast cancer breakthroughs leading to new drug targets, lifesaving treatments, and improved diagnostic and screening techniques. For World Breast Cancer Research Day, we present five of our top breast cancer–related stories from the past year, starting with a look back at one of the biggest breakthroughs of the past four decades.
From trading faxes to changing lives
When you bring together the best minds in biology, lifesaving science is bound to come to the surface. Case in point: a chance encounter in the early 1990s between then-CSHL scientist David Beach and future CSHL Trustee Charles Sherr revealed that the two investigators were following the same lead. Months later, they’d publish back-to-back papers on a protein called cyclin D. Soon thereafter, Sherr identified the cyclin-dependent kinase CDK4, which forms a complex with cyclin D.
Charles Sherr (left) and David Beach (right). Image: Paul Fetters, HHMI
If the clinical implications weren’t apparent then, they would be in time. In 2015, a quarter-century after Beach and Sherr met, the FDA approved palbociclib (marketed as Ibrance) for the treatment of HR-positive, HER2-negative breast cancer. The drug works by targeting CDK4 and CDK6, identified by another former CSHL scientist, Ed Harlow. Taken with hormone therapy, palbociclib has been shown to increase patient survival by more than two years and reduce tumor size by more than 50%.
Palbociclib has become an increasingly common part of clinical breast cancer therapies. It’s now widely considered a “first-line” therapy against HR-positive, HER2-negative breast cancer. And just last October, the FDA approved a new combination therapy using palbociclib in certain cases of advanced or metastatic breast cancer.
A new ‘link’ to triple-negative breast cancer
Triple-negative breast cancer (TNBC) accounts for 10 to 15 percent of all breast cancer cases. It disproportionately affects younger and African American women. No effective therapies exist. As seen on News12, a new discovery by CSHL Professor David Spector and graduate student Wenbo Xu could help point toward the first.
This triple-negative breast cancer organoid was grown in the lab using tissue samples donated by a volunteer patient. LINC01235 is seen in red.
Spector’s group discovered that a rarely studied long non-coding RNA (lncRNA) called LINC01235, previously implicated in gastric cancer, plays a part in TNBC, too. When the team knocked out LINC01235, they found that reducing the RNA’s production suppressed TNBC organoid formation.
Much more research would be needed for scientists to identify a potential treatment for TNBC. However, Spector says, these findings highlight the importance of non-coding RNAs in that search. “Our long-term goal is to try to find a lncRNA or multiple lncRNAs that may eventually be therapeutic targets,” he says.
Women’s health panel
Links between breast cancer and pregnancy can be hard to discuss. Maybe that’s why many of us don’t hear about them in high school health class or on the evening news. For CSHL Associate Professor Camila dos Santos, that’s precisely why the conversation needs to be had.
CSHL Associate Professor Camila dos Santos leads a panel discussion featuring certified OB/GYN Adrienne Mandelberger, Northwell Health Director of Cancer, Pregnancy & Reproduction Ruby Sharma, and Lizelle Comfort, a clinical fellow at Long Island Jewish Medical Center.
Last October, for Breast Cancer Awareness Month, CSHL hosted an event at Grace Auditorium along with Pink Aid. Here, dos Santos delved into the established links between pregnancy and cancer risk. She also spoke about a fascinating study on the potential effects of urinary tract infections on breast health. The talk opened up a lively panel discussion covering a range of women’s health issues.
Importantly, the conversation wasn’t just between scientists and clinicians. An audience of breast cancer survivors and other members of the public also participated. They offered up difficult but important questions that many women may have considered over the years. The event provided a public forum for those questions to be asked and answered honestly.
How breast cancer goes hungry
Last August, CSHL Associate Professor Michael Lukey reported a new way to deprive cancer cells of both a vital nutrient and their backup supply of that nutrient. In lab experiments with breast cancer cells, patient-derived tissue models, and mice, this strategy killed breast cancer cells and shrank tumors.
CSHL Associate Professor Michael Lukey has found that when glutamine and PHGDH (above, in green) are simultaneously depleted in breast cancer cells, it stunts their growth.
Previous studies have shown that starving cancer cells of glutamine or preventing its conversion into metabolites can stop the cells’ growth in the lab. However, breast cancer cells adapt to glutamine starvation by switching on a pathway that generates a critical metabolite called alpha-ketoglutarate, normally derived from glutamine.
Inhibitors of both metabolic pathways are now under further investigation. Lukey notes that these pathways might be especially important for breast cancer metastasis to different tissues, including some that are very difficult to treat. He hopes his lab’s combination therapy could ultimately improve the efficacy of glutamine metabolism inhibitors in the clinic. This could mean new effective treatments that target cancer’s metabolic addictions.
A commitment to giving back
Evelyn and Arlindo Jorge believed in philanthropy. The couple wanted to instill in their young family a commitment to giving back. So, every year around the holidays, they asked each of their grandchildren to submit a “proposal” to support something important to them. As a young girl, Stephanie Gibbons suggested her grandparents fund graphing calculators for classrooms and meals for senior citizens.
On November 20, 2024, Judy Jorge (front row, third from the left), Stephanie Gibbons (front row, fifth from the left), and other members of the Jorge Family Foundation joined with CSHL President Bruce Stillman (back row, last on the right) and Associate Professor Camila dos Santos (front row, last on the right) to support research on breast cancer and women’s health.
Losing her mother, Nancy Jorge Torcivia, to breast cancer in 1995 sharpened Gibbons’ philanthropic focus. Now a CSHL Association Director, she proudly continues her family’s tradition of community support. The breast cancer research coming out of Camila dos Santos’ lab recently inspired Gibbons and her family in the Arlindo and Evelyn Jorge Family Foundation to make a generous $1 million donation to CSHL. Thanks to the Jorge family, CSHL was able to completely renovate the dos Santos lab. This revitalization helps ensure that the lab’s crucial research on breast cancer and women’s health will continue for years to come.
Breast cancer research at Cold Spring Harbor Laboratory is made possible in part through the support of private donors. Would you like to find out more? Visit our breast cancer archive for more inspiring stories like these, or go to our Giving page to see how you, too, can help inspire CSHL’s next breast cancer breakthrough.
Written by: Communications Department | publicaffairs@cshl.edu | 516-367-8455
Stay informed
Sign up for our newsletter to get the latest discoveries, upcoming events, videos, podcasts, and a news roundup delivered straight to your inbox every month.
Moving day is officially approaching for Prince William and Kate Middleton.
Multiple outlets, including the Times of London, report that the Prince and Princess of Wales will soon live at Forest Lodge in Windsor. The news comes after weeks of rumors about a relocation from their current home of Adelaide Cottage. Previous articles suggested that Fort Belvedere, the former home of the Duke of Windsor, was on the table.
Yet the couple has settled on a different, yet equally grand property. The eight-bedroom, Georgian-style home (which dates back to the 1750s) is nestled within the 4,800 acres of Windsor Great Park. Its brick facade features stucco pilasters as well as an expansive view: “From both fronts the house commands varied and extensive views of the forest, the Great Park, the castle and town of Windsor, with a fine stretch of distant country,” wrote Jane Roberts in her 1997 book Royal Landscape: The Gardens and Parks of Windsor. She also found that accounts of the home from the 1800s mentioned a garden by Humphry Repton. (Although no modern reports have confirmed whether it still exists.) Also on the grounds? A tennis court, a paddock, and a small lake. And inside, you’ll find both a sitting and drawing room boasting marble fireplaces.
The grounds surrounding Forest Lodge in Windsor Great Park.
The Honor Magic V5 will launch in the UK alongside other European markets on August 28. (Image source: Honor)
Following a launch in July in China and a rollout in select Asian and European markets, the Honor Magic V5 will get a wider rollout soon. Honor has announced a launch date for the foldable in the UK. It will also launch on the same day in France, Germany, and Italy.
Honor is ready to bring its latest foldable smartphone, the Honor Magic V5 to more markets. The smartphone, which was first launched in China, is already available in some other markets including Hong Kong, Malaysia, and the Czech Republic. Now, Honor has set a launch date for the phone’s wider roll-out.
The Honor Magic V5 will be unveiled at a special event on August 28 at The Peninsula in London. According to the invite, it will also come along with a couple of other products such as the MagicPad 3, MagicBook Art 14 2025, and MagicBook Pro 14 2025.
While the launch event will be happening in London, Honor’s website shows that the Magic V5 will also be launching on the same date in France, Germany, Italy, and Spain. There are already product pages for the Magic V5 in these regions, but like in the UK, the price is yet to be revealed. Registrations have opened for the new phone, and those who sign up can score discounts and free gifts.
The Honor Magic V5 will be available in Europe in Ivory White, Dawn Gold, and Black. However, it seems Honor is making the Reddish Brown/Silk Brown exclusive to Asia.
Habeeb Onawole – Magazine Writer – 805 articles published on Notebookcheck since 2023
I love writing about consumer technology and have written thousands of articles that help people make informed decisions or get the best out of their devices. When I am not working, I am catching up on movies and TV shows or logging in hours on my Nintendo Switch or PlayStation.
